{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:52:37Z","timestamp":1792644757427,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1124\/mol.111.071654","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T12:34:03Z","timestamp":1307104443000},"page":"389-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Comparison of Direct Action of Thiazolidinediones and Glucocorticoids on Renal Podocytes: Protection from Injury and Molecular Effects"],"prefix":"10.1016","volume":"80","author":[{"given":"Shipra","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Guess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Benndorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.111.071654_bib1","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1096\/fj.09-134684","article-title":"Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action","volume":"23","author":"Ayroldi","year":"2009","journal-title":"FASEB J"},{"key":"10.1124\/mol.111.071654_bib2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jaci.2004.09.001","article-title":"Mitogen-activated protein kinase pathways: therapeutic targets in steroid resistance?","volume":"114","author":"Bloom","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1124\/mol.111.071654_bib3","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/db06-1134","article-title":"Peroxisome proliferator activated receptor alpha\/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db\/db mice","volume":"56","author":"Cha","year":"2007","journal-title":"Diabetes"},{"key":"10.1124\/mol.111.071654_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2174\/156802608784535011","article-title":"Glucocorticoid receptor antagonists","volume":"8","author":"Clark","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/mol.111.071654_bib5","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.bmcl.2008.01.027","article-title":"1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity","volume":"18","author":"Clark","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/mol.111.071654_bib6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"key":"10.1124\/mol.111.071654_bib7","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1124\/mol.105.012260","article-title":"Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling","volume":"68","author":"Gardner","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.111.071654_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ncpendmet0397","article-title":"Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors","volume":"3","author":"Gervois","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1124\/mol.111.071654_bib9","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2174\/092986708785132889","article-title":"Therapeutical relevance of MAP-kinase inhibitors in renal diseases: current knowledge and future clinical perspectives","volume":"15","author":"Grande","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1124\/mol.111.071654_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1523-1755.2001.00766.x","article-title":"Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease","volume":"60","author":"Guan","year":"2001","journal-title":"Kidney Int"},{"key":"10.1124\/mol.111.071654_bib11","doi-asserted-by":"crossref","first-page":"F845","DOI":"10.1152\/ajprenal.00161.2010","article-title":"Dose- and time-dependent glucocorticoid receptor signaling in podocytes","volume":"299","author":"Guess","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/mol.111.071654_bib12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1750-2187-4-6","article-title":"Glucocorticoid evoked upregulation of RCAN1-1 in human leukemic CEM cells susceptible to apoptosis","volume":"4","author":"Hirakawa","year":"2009","journal-title":"J Mol Signal"},{"key":"10.1124\/mol.111.071654_bib13","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00467-008-0792-3","article-title":"Therapies for steroid-resistant nephrotic syndrome","volume":"23","author":"Hodson","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1124\/mol.111.071654_bib14","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1124\/mol.104.004895","article-title":"Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway","volume":"67","author":"Ialenti","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.111.071654_bib15","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1210\/endo.140.7.6797","article-title":"Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells","volume":"140","author":"Johnson","year":"1999","journal-title":"Endocrinology"},{"key":"10.1124\/mol.111.071654_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2215\/CJN.02310508","article-title":"Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group","volume":"4","author":"Joy","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/mol.111.071654_bib17","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/sj.ki.5002248","article-title":"PPAR-gamma agonist protects podocytes from injury","volume":"71","author":"Kanjanabuch","year":"2007","journal-title":"Kidney Int"},{"key":"10.1124\/mol.111.071654_bib18","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jacc.2008.06.012","article-title":"Pharmacological differences of glitazones: does peroxisome proliferator-activated receptor-alpha activation make the difference?","volume":"52","author":"Kintscher","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/mol.111.071654_bib19","first-page":"1","article-title":"Peroxisome proliferator-activated receptor gamma and cancers","volume":"9","author":"Koeffler","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.111.071654_bib20","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1681\/ASN.2004121084","article-title":"Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome","volume":"16","author":"Koshikawa","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/mol.111.071654_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejphar.2009.03.005","article-title":"Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats","volume":"609","author":"Lahiri","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/mol.111.071654_bib22","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1007\/s00125-009-1423-7","article-title":"Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1","volume":"52","author":"Lennon","year":"2009","journal-title":"Diabetologia"},{"key":"10.1124\/mol.111.071654_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1440-1797.2009.01146.x","article-title":"Thiazolidinedione attenuate proteinuria and glomerulosclerosis in Adriamycin-induced nephropathy rats via slit diaphragm protection","volume":"15","author":"Liu","year":"2010","journal-title":"Nephrology"},{"key":"10.1124\/mol.111.071654_bib24","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1523-1755.2001.0590051899.x","article-title":"Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats","volume":"59","author":"Ma","year":"2001","journal-title":"Kidney Int"},{"key":"10.1124\/mol.111.071654_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1210\/en.2008-0196","article-title":"Thiazolidinediones are partial agonists for the glucocorticoid receptor","volume":"150","author":"Matthews","year":"2009","journal-title":"Endocrinology"},{"key":"10.1124\/mol.111.071654_bib26","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.58.4.5","article-title":"International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors","volume":"58","author":"Michalik","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1124\/mol.111.071654_bib27","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1074\/jbc.M410616200","article-title":"Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists","volume":"280","author":"Nie","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.111.071654_bib28","doi-asserted-by":"crossref","unstructured":"Pengal R, Guess AJ, Agrawal S, Manley J, Ransom RF, Mourey RJ, Benndorf R, Smoyer WE (2011) Inhibition of the protein kinase MK-2 protects podocytes from nephrotic syndrome-related injury. Am J Physiol Renal Physiol doi:10.1152\/ajprenal.00661.2010.","DOI":"10.1152\/ajprenal.00661.2010"},{"key":"10.1124\/mol.111.071654_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2369-11-2","article-title":"Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group","volume":"11","author":"Peyser","year":"2010","journal-title":"BMC Nephrol"},{"key":"10.1124\/mol.111.071654_bib30","doi-asserted-by":"crossref","first-page":"F213","DOI":"10.1152\/ajprenal.90421.2008","article-title":"Inducible rodent models of acquired podocyte diseases","volume":"296","author":"Pippin","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/mol.111.071654_bib31","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/j.1523-1755.2005.00723.x","article-title":"Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization","volume":"68","author":"Ransom","year":"2005","journal-title":"Kidney Int"},{"key":"10.1124\/mol.111.071654_bib32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.ajkd.2004.08.039","article-title":"Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy","volume":"45","author":"Sakai","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/mol.111.071654_bib33","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","article-title":"Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis","volume":"55","author":"Sarafidis","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/mol.111.071654_bib34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s001090050206","article-title":"Regulation of podocyte structure during the development of nephrotic syndrome","volume":"76","author":"Smoyer","year":"1998","journal-title":"J Mol Med"},{"key":"10.1124\/mol.111.071654_bib35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1096\/fj.01-0681com","article-title":"Hsp27 regulates podocyte cytoskeletal changes in an in vitro model of podocyte process retraction","volume":"16","author":"Smoyer","year":"2002","journal-title":"FASEB J"},{"key":"10.1124\/mol.111.071654_bib36","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1210\/en.2006-0981","article-title":"Minireview: rapid glucocorticoid signaling via membrane-associated receptors","volume":"147","author":"Tasker","year":"2006","journal-title":"Endocrinology"},{"key":"10.1124\/mol.111.071654_bib37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1172\/JCI119278","article-title":"Aldosterone and dexamethasone stimulate calcineurin activity through a transcription-independent mechanism involving steroid receptor-associated heat shock proteins","volume":"99","author":"Tumlin","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1124\/mol.111.071654_bib38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1210\/jc.2002-020354","article-title":"Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability","volume":"88","author":"Vermeer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/mol.111.071654_bib39","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.ki.5001655","article-title":"Direct effects of dexamethasone on human podocytes","volume":"70","author":"Xing","year":"2006","journal-title":"Kidney Int"},{"key":"10.1124\/mol.111.071654_bib40","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1681\/ASN.2008111138","article-title":"The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury","volume":"20","author":"Yang","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/mol.111.071654_bib41","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1038\/sj.ki.5000336","article-title":"Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis","volume":"69","author":"Yang","year":"2006","journal-title":"Kidney Int"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24032723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24032723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.111.071654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:12:19Z","timestamp":1739959939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24032723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0026895X24032723"],"URL":"https:\/\/doi.org\/10.1124\/mol.111.071654","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Direct Action of Thiazolidinediones and Glucocorticoids on Renal Podocytes: Protection from Injury and Molecular Effects","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.111.071654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}